Lana E. Kandalaft

9.3k total citations
93 papers, 3.8k citations indexed

About

Lana E. Kandalaft is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Lana E. Kandalaft has authored 93 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Immunology, 62 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Lana E. Kandalaft's work include Immunotherapy and Immune Responses (63 papers), Cancer Immunotherapy and Biomarkers (47 papers) and CAR-T cell therapy research (31 papers). Lana E. Kandalaft is often cited by papers focused on Immunotherapy and Immune Responses (63 papers), Cancer Immunotherapy and Biomarkers (47 papers) and CAR-T cell therapy research (31 papers). Lana E. Kandalaft collaborates with scholars based in Switzerland, United States and United Kingdom. Lana E. Kandalaft's co-authors include George Coukos, Cheryl Lai-Lai Chiang, Alexandre Harari, Daniel J. Powell, Michele Graciotti, Michal Bassani‐Sternberg, Klara Balint, János L. Tanyi, Philippe O. Gannon and Kunle Odunsi and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lana E. Kandalaft

90 papers receiving 3.8k citations

Peers

Lana E. Kandalaft

IMMUN

ONCOL

PRM

Nathalie Scholler United States

Paulette Mhawech‐Fauceglia United States

Jitka Fučíková Czechia

Sebastian Kobold Germany

Sophia N. Karagiannis United Kingdom

Changyu Wang China

Michal Lotem Israel

Stefania Bellone United States

Jayanthi Lea United States

Aitziber Buqué United States

Nathalie Scholler United States

Lana E. Kandalaft

1.1k ×0.4

IMMUN

1.5k ×0.7

ONCOL

1.1k ×0.9

585 ×1.5

333 ×1.0

PRM

Citations per year, relative to Lana E. Kandalaft Lana E. Kandalaft (= 1×) peers Nathalie Scholler

Countries citing papers authored by Lana E. Kandalaft

Since Specialization

Citations

This map shows the geographic impact of Lana E. Kandalaft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lana E. Kandalaft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lana E. Kandalaft more than expected).

Fields of papers citing papers by Lana E. Kandalaft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lana E. Kandalaft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lana E. Kandalaft. The network helps show where Lana E. Kandalaft may publish in the future.

Co-authorship network of co-authors of Lana E. Kandalaft

This figure shows the co-authorship network connecting the top 25 collaborators of Lana E. Kandalaft. A scholar is included among the top collaborators of Lana E. Kandalaft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lana E. Kandalaft. Lana E. Kandalaft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Banerjee, Susana, Anita Wolfer, Petronella B. Ottevanger, et al.. (2025). Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study. Clinical Cancer Research. 31(11). 2145–2153. 3 indexed citations

Ferreira, Humberto J., Brian J. Stevenson, HuiSong Pak, et al.. (2024). Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides. Nature Communications. 15(1). 2357–2357. 22 indexed citations

Yakkala, Chakradhar, Jesús Corría-Osorio, Lana E. Kandalaft, et al.. (2024). Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma Model. Clinical Cancer Research. 30(18). 4190–4200. 2 indexed citations

Yu, Yi-Ru, Sheue‐Fen Tzeng, Jaeoh Park, et al.. (2024). Abstract 2370: Revitalizing anti-tumor immunity through PLT012 monoclonal antibody, targeting CD36 for metabolic rewiring in the tumor microenvironment. Cancer Research. 84(6_Supplement). 2370–2370.

Lozano, Leyder Elena, Sébastien Lofek, Béatris Mastelic-Gavillet, et al.. (2023). Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer. Cancers. 15(12). 3114–3114. 1 indexed citations

Yu, Yi-Ru, Chin‐Hsien Tsai, Jaeoh Park, et al.. (2023). 1401 PLT012, a monoclonal antibody targeting CD36, unleashes anti-tumor immunity via metabolic reprogramming in tumor microenvironment. SHILAP Revista de lepidopterología. A1559–A1559. 1 indexed citations

Mastelic-Gavillet, Béatris, Leyder Elena Lozano, Sébastien Lofek, et al.. (2023). Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy. Frontiers in Immunology. 14. 1119371–1119371. 4 indexed citations

Mark, Michael, Sylvie Rusakiewicz, Martin Früh, et al.. (2022). Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO Open. 7(3). 100446–100446. 5 indexed citations

Harari, Alexandre, Kaat de Jonge, Anne‐Christine Thierry, et al.. (2021). A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma. Cancers. 13(22). 5801–5801. 6 indexed citations

10.

Kandalaft, Lana E. & Alexandre Harari. (2021). Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. Cancers. 13(22). 5819–5819. 4 indexed citations

11.

Graciotti, Michele, Fabio Marino, HuiSong Pak, et al.. (2020). Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines. Vaccines. 8(2). 271–271. 15 indexed citations

12.

Dafni, U., Silvia Martin Lluesma, Klara Balint, et al.. (2020). Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis. European Journal of Cancer. 142. 63–82. 29 indexed citations

13.

Lluesma, Silvia Martin, Michele Graciotti, Alizée J Grimm, et al.. (2020). Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?. Current Opinion in Biotechnology. 65. 190–196. 13 indexed citations

14.

Guo, Yi, Yanfeng Wang, Xiaohui Peng, et al.. (2018). Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma. European Journal of Cancer. 90. 111–121. 26 indexed citations

15.

Herrera, Fernanda, Massimo Valério, Dominik Berthold, et al.. (2018). 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. International Journal of Radiation Oncology*Biology*Physics. 103(2). 320–334. 33 indexed citations

16.

Bassani‐Sternberg, Michal, Chloé Chong, Philippe Guillaume, et al.. (2017). Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Computational Biology. 13(8). e1005725–e1005725. 177 indexed citations

17.

Zsíros, Emese, Priyanka Duttagupta, Denarda Dangaj Laniti, et al.. (2015). The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research. 21(12). 2840–2850. 48 indexed citations

18.

Chiang, Cheryl Lai-Lai, Lana E. Kandalaft, János L. Tanyi, et al.. (2013). A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research. 19(17). 4801–4815. 181 indexed citations

19.

Kandalaft, Lana E., Cheryl Lai-Lai Chiang, János L. Tanyi, et al.. (2013). A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine. 11(1). 149–149. 53 indexed citations

20.

Kandalaft, Lana E., Enrique Zudaire, Sergio Portal‐Núñez, Frank Cuttitta, & Sonia B. Jakowlew. (2008). Differentially expressed nucleolar transforming growth factor-β1 target (DENTT) exhibits an inhibitory role on tumorigenesis. Carcinogenesis. 29(6). 1282–1289. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact